Drugs / MNPR-101-PCTA-177Lu
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06617169 | Oct 2024 → Dec 2026 expected | colorectal cancer, gastric cancer, lung cancer, malignant pancreatic neoplasm +4 | Monopar Therapeutics | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06980519 | — | cancer | Monopar Therapeutics | Available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNPR-101-PCTA-177Lu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06617169 ↗ |
| Modality | Monoclonal antibody | “MNPR-101-PCTA-177Lu is a monoclonal antibody-radionuclide conjugate intended to target and deliver radioactivity to solid tumors expressing uPAR.” NCT06980519 ↗ |
| Route | Intravenous | “MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes” NCT06617169 ↗ |